Parvus Therapeutics is Pharmaceuticals in United States that focus on Multiple Sclerosis business. Founded in 2006. They cover business area such as developer, therapeutic, autoimmune disease, immune tolerance, a rich pipeline, two lead drug candidate, clinical development, Multiple Sclerosis, (MS, drug product manufacture, GLP toxicology study.
2006
( 18 years old in 2024 )
Multiple Sclerosis
-
800 Dubuque Avenue
South San Francisco
San Francisco, CA 94080
United States
Private
developertherapeuticautoimmune diseaseimmune tolerancea rich pipelinetwo lead drug candidateclinical developmentMultiple Sclerosis(MSdrug product manufactureGLP toxicology study
* We use standard office opening hours in near Parvus Therapeutics's location as default value for unknown and outdated data. For more valid info, please verify the info from more trusted sources like GoogleMyBusiness, Yelp, FourSquare or similar services.
Parvus Therapeutics is Pharmaceuticals business from United States that founded in 2006 (18 years old in 2024), Parvus Therapeutics business is focusing on Multiple Sclerosis.
Parvus Therapeutics headquarter office and corporate office address is located in 800 Dubuque Avenue South San Francisco San Francisco, CA 94080 United States.
Parvus Therapeutics was founded in United States.
In 2024, Parvus Therapeutics is currently focus on Multiple Sclerosis sector.
Above is snippet of Google Trends for "Multiple Sclerosis" term, if you have problem loading the snippet, please visit here: Google Trend.
Disclaimer: This website is not affiliated with Parvus Therapeutics, any government agency, does not create this data, vouch for its accuracy, or guarantee that it is the most recent data available. The data displayed is available through open government websites and public online directory. This website expressly disclaims the accuracy, adequacy, or completeness of any data and shall not be liable for any errors, omissions or other defects in, delays or interruptions in such data, or for any actions taken in reliance thereon.
